The postantibiotic effect (PAE) of tomopenem was determined after a 2 h exposure of two strains of meticillin-susceptible and meticillin-resistant Staphylococcus aureus (MSSA and MRSA), and imipenem-susceptible and imipenem-resistant Pseudomonas aeruginosa, to tenfold the respective MIC. The PAEs on MSSA and P. aeruginosa were approximately 1 h and they were comparable to those of meropenem. The PAE on MRSA was 1.5 to 3 h, equal to or longer than those of vancomycin. The PAEs of tomopenem not only were found for MRSA, but also were present in the imipenem-resistant P. aeruginosa tested.
INTRODUCTION
Tomopenem (formerly CS-023) is a novel 1b-methyl carbapenem with a broad spectrum of activity against clinically important Gram-positive and Gram-negative bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. We have previously reported that the favourable features of tomopenem are as follows: (i) better antibacterial activity against P. aeruginosa than imipenem and meropenem, and in particular, potent activity against imipenem-resistant P. aeruginosa (Koga et al., 2005) ; (ii) correlation between the potent antibacterial activity against MRSA and a high affinity for penicillinbinding protein 2a (Koga et al., 2008) ; and (iii) a longer elimination half-life than imipenem and meropenem in clinical studies (Shibayama et al., 2006) . The purpose of this study was to determine the in vitro postantibiotic effects (PAEs) of tomopenem on meticillinsusceptible S. aureus (MSSA), MRSA, imipenem-susceptible P. aeruginosa, and imipenem-resistant P. aeruginosa and to compare them with the PAEs of the antibiotics routinely used in clinical practice to treat infections caused by these pathogens.
METHODS
Antibiotics. Tomopenem was synthesized at Daiichi Sankyo Research Laboratories, Tokyo, Japan. Pure samples of imipenem (Banyu Pharmaceutical), meropenem (Dainippon Sumitomo Pharma) and ceftazidime (GlaxoSmithKline) were extracted at Daiichi Sankyo from commercially supplied compounds. Vancomycin hydrochloride was purchased from Sigma-Aldrich.
Bacterial strains. MRSA 12404, MRSA 12412, and imipenemresistant P. aeruginosa 12435 and 12438 (metallo-b-lactamase-negative strains) were isolated in Japanese hospitals in 1999. The reference strains used in this study were stock cultures from our laboratory.
Susceptibility tests. The MICs were determined by a standard microdilution broth method (CLSI, 2006 PAE. The PAE was determined by the viable plate count method (Craig & Gudmundsson, 1996) . The organisms were freshly subcultured and incubated at 37 uC with shaking to obtain a final inoculum of approximately 5610 6 c.f.u. ml
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. Bacterial suspensions of each organism were then exposed to 106MIC of each compound for 2 h. A culture containing no compound was included as a growth control. At the end of the exposure period, the cultures were diluted 1000-fold with CAMHB in order to remove the compounds. Viable counts were determined for all cultures at this time (time 0). The cultures were placed back in a shaker, with sampling performed every hour on heart infusion agar plates. The 10-fold serially diluted samples (diluted with CAMHB) were pipetted into a sterile Petri plate and 10 ml melted heart infusion agar was added. Three independent tests were carried out for each bacterial strain.
For calculation of the PAE (min), the PAE was defined as T2C, where T represents the time required for the count in the compound-exposed culture to increase by 1 log 10 above the count observed at time 0, and where C is the corresponding time for the control culture. Each PAE was calculated independently. The mean and its 95 % confidence interval for each PAE were determined using SAS system release 8.2.
Statistical analysis. A t test was performed with the hypothesis that the mean PAE of the three experiments was equal to 0 for each compound. A P value of less than 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Tomopenem has enhanced activity against MRSA and P. aeruginosa, and improved pharmacokinetic properties in comparison with commercially available carbapenems such as imipenem and meropenem. Carbapenems induce a consistent PAE both in vitro and in vivo against both Gram-positive and Gram-negative bacteria, including P. aeruginosa (Odenholt et al., 1989) . However, very few data have been reported regarding the PAE of carbapenems on MRSA and imipenem-resistant P. aeruginosa. Therefore, in this study we determined the PAEs on these pathogens. Since the duration of the PAE increased until a maximum response was obtained, usually at a concentration that was approximately 106MIC (Vogelman & Craig, 1985; Zhanel et al., 1991) , we chose this concentration. Table 1 shows the PAEs of tomopenem against S. aureus and P. aeruginosa. For MSSA, the PAEs of tomopenem were almost the same as those of imipenem, meropenem and ceftazidime. For MRSA 12412, the PAEs of tomopenem were longer than those of vancomycin. MacGowan et al. (2008) reported that tomopenem had a superior effect compared to vancomycin in an in vitro pharmacokinetic model of MRSA infection, possibly because of its longer PAE. For P. aeruginosa ATCC 27853, the PAE of imipenem in the current study is similar to that in another report (Odenholt et al., 1989) . The PAEs of tomopenem for P. aeruginosa were almost the same as those of meropenem, and were slightly shorter than those of imipenem. Ceftazidime showed negative PAEs against two strains of P. aeruginosa. Ceftazidime showed a high affinity to PBP 3 and caused a filament formation on Gram-negative bacteria, which therefore produced negative PAEs. On the contrary, Gould et al. (1989) expressed the notion that an affinity to PBP 2 is related to the induction of PAE. Since tomopenem binds to PBP 2 in P. aeruginosa with high affinity that results in bulge formations on cells (Koga et al., 2009) , it showed positive PAEs, as did the other carbapenems. For the imipenem-resistant P. aeruginosa tested, the PAEs of tomopenem were almost the same as those of meropenem, and the PAEs on imipenemsusceptible and -resistant isolates were no different. The reason for this is not clear; however, the PAEs may not be different between susceptible and resistant strains on the basis of MIC. Since there have been reports about various types of MRSA (Hanssen & Ericson Solid, 2006 ) and carbapenem-resistant P. aeruginosa (Quale et al., 2006) , further study is required on tomopenem against additional strains to provide more detailed information about PAEs.
Tomopenem has a longer half-life (1.7 h) in comparison with imipenem (Drusano & Standiford, 1985) and meropenem (Bax et al., 1989) , and the protein binding value of tomopenem in human serum is low (9.5 %; Shibayama et al., 2007) , similar to those of imipenem and meropenem. Since we have shown that the activity of tomopenem against S. aureus and P. aeruginosa was minimally affected by twofold with the addition of horse serum (Ohya et al., 2000) , it is suggested that serum would have little impact on the PAEs. A single 1400 mg dose in healthy Caucasian volunteers (Shibayama et al., 2006) and a 1500 mg dose in healthy Japanese volunteers (Sesoko et al., 2006) yielded maximum concentrations in serum of 102±15 and 122±14 mg l 21 , respectively. At these doses, the concentrations in serum could exceed 40 mg l 21 in about 2 h. Since the MIC of tomopenem against MRSA and the imipenem-resistant P. aeruginosa tested was 4 mg l 21 , tomopenem may help prevent the regrowth of these bacteria if the drug levels drop below the MIC between doses for these organisms. In addition to the PAEs, the effect of subinhibitory concentrations on bacteria previously treated (the postantibiotic subMIC effect) or not (subMIC effect) is another important parameter (Odenholt-Tornqvist et al., 1991) . The postantibiotic subMIC effect represents the time interval that includes the PAE plus the additional time during which growth is suppressed by subMIC concentrations. The postantibiotic subMIC effect and subMIC effect reflect serum drug levels that may exist between antibiotic dosing intervals and the success of discontinuous dosing regimens. These parameters should also be considered in the event that an optimal dosage regimen for tomopenem can be determined.
